Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Recruiting Phase 2 Interventional

A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

ClinicalTrials.gov ID: NCT05795465

Public ClinicalTrials.gov record NCT05795465. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 28, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2, Two-Part Study to Evaluate the Safety and Tolerability of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

GEn1E-1124-002 is a two-part Phase 2 study to evaluate the safety and tolerability of GEn-1124 in subjects with ARDS. Treatment with IV infusion dosing as early as possible after ARDS diagnosis. Subjects will be given a second dose approximately 8 hours after the first dose and will continue with twice daily dosing (BID regimen) for 5 days.

Study identification

NCT ID
NCT05795465
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
GEn1E Lifesciences
Industry
Enrollment
52 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 85 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Apr 3, 2023
Primary completion
Sep 30, 2026
Completion
Nov 30, 2026
Last update posted
Jun 22, 2026

2023 – 2026

United States locations

U.S. sites
11
U.S. states
10
U.S. cities
11
Facility City State ZIP Site status
Medstar Washington Hospital Center Washington D.C. District of Columbia 20010 Withdrawn
University of Kansas Medical Center Kansas City Kansas 66160 Withdrawn
University of Maryland Medical Center Baltimore Maryland 21201 Recruiting
University of Maryland - Baltimore Washington Medical Center Glen Burnie Maryland 21061 Recruiting
Ocean Springs Hospital Ocean Springs Mississippi 39564 Completed
Washington University School of Medicine St Louis Missouri 63110 Withdrawn
Cooper University Hospital Camden New Jersey 08103 Recruiting
The Mount Sinai Hospital New York New York 10029 Withdrawn
Cleveland Clinic Cleveland Ohio 44195 Recruiting
Houston Methodist Hospital Houston Texas 77030 Withdrawn
Intermountain Medical Center Murray Utah 84107 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05795465, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 22, 2026 · Synced Sep 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05795465 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →